Please ensure Javascript is enabled for purposes of website accessibility

Abiomed Soars 16% on Acquisition and an Earnings Beat

By Jim Crumly – Apr 30, 2020 at 2:06PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Also, the company's products could help keep COVID-19 patients alive.

Shares of Abiomed (ABMD 0.09%), a maker of medical devices that improve heart function, soared after the company announced the acquisition of a company that has developed a portable artificial lung and also reported better-than-expected earnings for its fiscal fourth quarter. In addition, the company reported that its implantable heart pump had been successful in helping a pair of critically ill COVID-19 patients survive the disease.

Abiomed has acquired Breethe, a private company that has developed a compact extracorporeal membrane oxygenation (ECMO) system -- an artificial lung for patients suffering from cardiogenic shock or respiratory failure. Abiomed believes the acquisition will complement its Impella heart pump product by supporting heart failure patients whose lungs can no longer provide sufficient oxygenation, including patients with viral diseases such as COVID-19. Terms of the deal were not released.

Heart inside a man, with EKG pattern superimposed.

Image source: Getty Images.

Revenue in the quarter was flat year-over-year at $207 million, but would have been up about 8% without the effect of the pandemic on the company's business in March. Earnings per share, excluding an unrealized investment loss and a tax benefit, fell 8% to $0.98, which beat analysts' consensus estimate of $0.94.

Abiomed described on the conference call how its Impella heart pump had saved the lives of two critically ill COVID-19 patients who had developed cardiovascular complications due to severely affected lungs. The company believes that wider use of Impella in COVID-19 patients could save lives by stabilizing such patients while antiviral treatments take effect.

Jim Crumly has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Abiomed. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Abiomed Stock Quote
Abiomed
ABMD
$264.25 (0.09%) $0.24

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.